Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 16 EP applications Anders Kassow has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 16, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11702650

AGONIST DR5 BINDING POLYPEPTIDES

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
Novartis AG
Applicant:
Ablynx N.V.
Agent:
Anders Kassow, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12173018

HUMAN ANTIBODIES AGAINST IL13 AND THERAPEUTIC USES

IPC classification:
A61K 39/395, C07K 16/00, C07K 16/24
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
PATENT GRANTED
EP11785367

CXCR2 BINDING POLYPEPTIDES

IPC classification:
C07K 16/28
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12768999

FUSION PROTEINS FOR TREATING METABOLIC DISORDERS

IPC classification:
A61K 47/48, C07K 14/50
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Agent:
Daniela Gill-Carey, Novartis Pharmaceuticals UK Limited
Status:
GRANT OF PATENT INTENDED
EP12173002

HUMAN ANTIBODIES AGAINST IL13 AND THERAPEUTIC USES

IPC classification:
A61K 39/395, C07K 16/00, C07K 16/24
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12172979

HUMAN ANTIBODIES AGAINST IL13 AND THERAPEUTIC USES

IPC classification:
A61K 39/395, C07K 16/00, C07K 16/24
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13721396

TREATMENT OF FIBROSIS

IPC classification:
A61K 39/395, A61P 19/04
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13744818

ANTIBODY FORMULATION

IPC classification:
A61K 9/00, A61K 39/395, A61K 47/18, A61K 47/26, C07K 16/28
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP13735529

BIOMARKERS ASSOCIATED WITH CDK INHIBITORS

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Applicant:
Dana-Farber Cancer Institute, Inc.
Agent:
Anders Kassow, Novartis Pharma AG
Status:
The patent has been granted
EP11785007

METHODS OF TREATING FGF21-ASSOCIATED DISORDERS

IPC classification:
C07K 14/50
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13812296

COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO

IPC classification:
A61K 39/00, C07K 16/22
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13815922

COMPOSITIONS AND METHODS THAT UTILIZE A PEPTIDE TAG THAT BINDS TO HYALURONAN

IPC classification:
C07K 14/47, C12N 15/62
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14713728

PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE

IPC classification:
A61K 38/18, C07K 14/475
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14714794

NOTCH2 BINDING MOLECULES FOR TREATING RESPIRATORY DISEASES

IPC classification:
C07K 16/28
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14710440

MARKERS FOR ISOCITRATE DEHYDROGENASE INHIBITORS

IPC classification:
C12Q 1/68
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP15731117

PULMONARY HYPERTENSION BIOMARKER

IPC classification:
C12Q 1/68, G01N 33/68
Applicant:
Novartis AG
Agent:
Anders Kassow, Novartis Pharma AG
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature